Meta-analysis of gemcitabine plus nab-paclitaxel combined with targeted agents in the treatment of metastatic pancreatic cancer

Table 1 Characteristics of the eligible trials included in this systematic analysis of data on gemcitabine plus nab-paclitaxel + a targeted drug in metastatic pancreatic cancer

Ref.	Median age	Gender (f/m)	Treatment	Media OS (mo)	Median PFS (mo)	ORR [n (%)]
Kundranda et al[26]	60	16/27	GA+ istiratumab	8.7	3.6	17 (39.5%)
	60	26/19	GA+ Placebo	11.7	7.1	22 (51.2%)
Ko et al[29]	66.5	29/37	GA+ apatorsen	5.3	2.7	12 (18%)
	65.5	28/38	GA+ Placebo	6.9	3.8	12 (18%)
O’Reilly et al[30]	65	33/29	GA+ necuparanib	10.71	5.52	14 (23%)
	61	25/33	GA+ placebo	9.99	6.93	8 (14%)
Karasic et al[28]	65	45/67	GA+ HCQ	11.1	5.7	21 (38.2%)
			GA+ Placebo	12.1	6.4	12 (22.1%)
Tempero et al[32]	64	97/114	GA+ Ibrutinib	9.69	5.32	62 (29%)
	64	92/120	GA+ Placebo	10.78	6.03	90 (42%)
Hu et al[31]	66	39/50	GA+ Tarextumab	6.4	3.7	18 (20%)
	66	34/54	GA+ Placebo	7.9	5.5	28 (32%)
Van Cutsem et al[27]	63.8	147/180	GA+PEGPH20	11.2	7.1	153 (47%)
	62.3	85/80	GA+Placebo	11.5	7.1	59 (36%)

OS: Overall survival; ORR: Objective response rates; f/m: Female/male; PFS: Progression-free survival; GA: Gemcitabine plus nab-paclitaxel; HCQ: Hydroxychloroquine.